Resources
26 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.
Posted 12/8/2021 (updated 3/27/2024)
This week, the federal agency that researches what makes health care safer, more affordable, higher quality, and accessible to all released its compendium of data and trends for rural populations. The chartbook is part of the annual National Healthcare Quality and Disparities Report (NHQDR) that assesses the performance of our health care system across these measures.
Posted 6/14/2022 (updated 3/27/2024)
On Wednesday, the U.S. Department of Health & Human Services announced nearly $15 million awarded to rural communities to continue addressing misuse of illegal and prescription drugs known as psychostimulants. These awards are part of the Rural Communities Opioid Response Program (RCORP), a multi-year initiative with $400 million invested since its start in 2018.
Posted 8/2/2022 (updated 3/27/2024)
A new brief from the National Center for Health Statistics gives geographic detail on the latest increase in overdose death rates. Overall, urban counties had higher rates, but eight states – California, Connecticut, Maryland, New York, North Carolina, North Dakota, Vermont, and Virginia – had rates that were higher in rural counties.
Posted 6/7/2022 (updated 3/27/2024)
We began with a critical examination of the history of family separation in the US to lay the groundwork for a discussion of both provider and patient trust and mistrust. The stigma and discrimination that pregnant, postpartum, and parenting people with substance use disorder was explored. We concluded with concrete suggestions to improve provider wellness, child development, and community cohesion.
Posted 1/24/2023 (updated 3/27/2024)
This webinar will introduce the newest RCORP program cohorts to the RCOEs, Fletcher Group, University of Rochester, and University of Vermont. These three cooperative agreements are charged with supporting the identification, translation, dissemination, and implementation of evidence-based programs and best practices, in addition to providing specialized TA to RCORP recipients and other rural providers.
Posted 1/31/2023 (updated 3/27/2024)
Providers are essential partners in care and have a very important role in reducing the various types of stigmas experienced by those with or recovering from substance use disorder (SUD) and their families; becoming an ally is the first step. Allyship includes a set of beliefs, attitudes, and actions; we will explore a variety of steps that can lead to greater empathy and better outcomes for clients, families, and communities.
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 7/7/2021 (updated 4/2/2024)
This presentation highlighted the intersection of discrimination, women, substance use and reproductive rights from historical and current perspectives. It then provided methods and techniques for eliminating stigma and discrimination on a provider-patient level and provide an opportunity for the audience to practice compassionate care.
Posted 7/21/2021 (updated 4/2/2024)
Goals: Increase knowledge of harm reduction principles, strategies, and resources, increase knowledge of managed use, abstinence, and safer use to meet people who use drugs where they are at, provide a safe environment (plenaries and breakouts) to discuss licit and illicit drug use as a multi-faceted phenomenon requiring successful interventions and policies and increase knowledge of stigma as it relates to harm reduction principles and practices.